Russell Investments Group Ltd. Buys 142,796 Shares of Option Care Health, Inc. $OPCH

Key Points

• Russell Investments Group Ltd. increased its holdings in Option Care Health, Inc. by 125.3%, acquiring an additional 142,796 shares and bringing its total ownership to 256,776 shares, valued at approximately $8.97 million.
• Option Care Health reported $0.41 earnings per share (EPS) for the quarter, slightly exceeding analysts' expectations, with revenues of $1.42 billion, a 15.4% year-over-year increase.
• Analyst ratings for Option Care Health have improved, with UBS Group upgrading it to a "buy" rating and raising the target price from $38 to $40, reflecting positive sentiment among analysts.

Russell Investments Group Ltd. lifted its position in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 125.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 256,776 shares of the company's stock after purchasing an additional 142,796 shares during the quarter. Russell Investments Group Ltd. owned 0.16% of Option Care Health worth $8,974,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in Option Care Health during the 1st quarter worth $70,965,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Option Care Health by 6,525,926.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock worth $52,459,000 after acquiring an additional 1,500,963 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Option Care Health during the fourth quarter worth about $27,428,000. Freestone Grove Partners LP acquired a new stake in shares of Option Care Health during the fourth quarter worth about $17,487,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Option Care Health by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after purchasing an additional 591,042 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company's stock.

Insider Buying and Selling at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. bought 36,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the purchase, the director owned 375,390 shares of the company's stock, valued at $10,191,838.50. This represents a 10.61% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction on Thursday, August 21st. The shares were purchased at an average cost of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the transaction, the director directly owned 49,229 shares of the company's stock, valued at approximately $1,354,289.79. This represents a 68.43% increase in their position. The disclosure for this purchase can be found here. 0.64% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on OPCH. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and increased their target price for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. Barrington Research reiterated an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. Citigroup reissued an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Finally, JMP Securities boosted their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.75.

Option Care Health Stock Down 2.4%

Shares of Option Care Health stock traded down $0.68 during trading hours on Monday, reaching $28.06. 1,896,405 shares of the company's stock were exchanged, compared to its average volume of 1,997,394. The stock has a market cap of $4.55 billion, a P/E ratio of 22.45, a P/E/G ratio of 1.75 and a beta of 0.79. The company has a 50 day moving average of $29.85 and a two-hundred day moving average of $31.74. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a fifty-two week low of $21.39 and a fifty-two week high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.01. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.Option Care Health's revenue was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts forecast that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.